Industry Leaders Launch Revolutionary Test for Early Alzheimer’s Detection
Circular Genomics and Vitazi.ai have joined forces to roll out a groundbreaking two-step diagnostic system that could transform how Alzheimer’s disease is detected across the United States and beyond. The urgent innovation combines advanced AI retinal imaging with cutting-edge circular RNA blood biomarkers to catch the disease long before symptoms appear, a major leap in battling a condition that currently lacks scalable early detection tools.
Alzheimer’s disease often goes unnoticed in its earliest stages, with diagnoses typically coming years after the disease begins damaging the brain. This delay hampers timely intervention and effective treatment. Now, Circular Genomics and Vitazi.ai’s partnership targets this critical gap with a non-invasive, cost-effective screening strategy that starts right in primary care or optometry offices nationwide.
How the Two-Step Screening Works
The new system begins with Vitazi.ai’s AI-powered retinal imaging scan, which analyzes structural and vascular changes in the retina—a window into neurological health. Patients flagged at risk then proceed to the second step: a blood test developed by Circular Genomics that detects brain-derived circular RNA biomarkers. These markers provide molecular precision, confirming early disease biology beyond traditional protein-based tests.
Paul Sargeant, CEO of Circular Genomics, emphasized that this tandem approach expands the platform from specialty clinics directly into primary care arenas, increasing accessibility and early detection rates dramatically. Jeremy Stueven, CEO of Vitazi.ai, praised the synergy of combining “complementary data modalities that reflect different dimensions of human biology.”
Why This Breakthrough Matters Now
The development arrives at a crucial moment when pharmaceutical companies and healthcare providers urgently need better tools to identify patients for clinical trials and early treatments. Disease-modifying therapies for Alzheimer’s are most effective when given early, but limited screening has blocked timely care.
The broad availability of AI retinal screening enables quick, non-invasive patient triage without requiring complex equipment, while the blood test’s high specificity reduces false positives and supports precise patient stratification. This scalable workflow is poised to change Alzheimer’s management on a massive scale, allowing health systems across Alabama and the U.S. to intervene earlier and improve outcomes.
Technical Innovation Meets Clinical Need
The core challenge lies in integrating data from two radically different sources: high-resolution retinal images and molecular RNA profiles from blood. Circular Genomics’ biomarkers are notably more stable and enriched in brain tissue, offering richer insight into disease pathways instead of isolated signals. This complexity demands sophisticated machine learning models that unify these datasets to deliver actionable clinical predictions.
Nikolaos Mellios, chief scientific officer at Circular Genomics, highlighted the broader potential beyond Alzheimer’s: “This represents a fundamental advancement in how we model and measure neurodegenerative disease biology, with implications that extend well beyond Alzheimer’s to precision neurology as a whole.”
Looking Ahead: A New Era in Neurodegenerative Disease Detection
The partnership between Circular Genomics and Vitazi.ai signals a paradigm shift in early detection, with the potential to reshape neurodegenerative disease screening across the U.S. and eventually globally. Healthcare providers, patients, and pharmaceutical partners stand to gain from earlier intervention windows, improved clinical trial recruitment, and more personalized therapies.
As this technology rolls out in primary care settings, including those in Alabama, the hope is clear: to catch Alzheimer’s before irreversible damage occurs and empower patients with timely, life-changing treatment options.
The latest innovation affirms the growing power of AI and molecular biology in healthcare, offering new hope for millions at risk of this devastating disease right now.
